Streetbeat News

Stock Prices

ICPT

Intercept Pharmaceuticals announced new data showing the potential of a fixed-dose combination of Obeticholic Acid and Bezafibrate to normalize multiple biomarkers in Primary Biliary Cholangitis.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:20 am

LOVE

Lovesac expects FY24 net sales of $700M-$740M, with EPS of $1.83-$2.24, in line with consensus estimates of $729.08M and $2.09 respectively.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:08 am

ATNM

Actinium Pharma is set to join the Russell 2000 and Russell 3000 indexes, which could lead to increased visibility and investment in the company.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:07 am

UNFI

United Natural Foods (UNFI) has lowered its FY23 adjusted EPS guidance from $3.05-$3.90 to $1.80-$2.30, compared to the estimated $3.32.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:06 am

UNFI

United Natural Foods (UNFI) has lowered its profitability outlook for FY23 due to supply chain disruptions and inflationary pressures.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:05 am

LOVE

Lovesac (LOVE) anticipates unfavorable macro-economic conditions to persist in the upcoming quarters, potentially impacting the company's performance.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:05 am

SSTK

Shutterstock has announced a share repurchase program of up to $100 million, aiming to return value to shareholders and increase shareholder confidence.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:03 am

COYA

Coya Therapeutics (NASDAQ:COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept clinical study for COYA 301 in patients with mild to moderate Alzheimer's Disease. The results will be presented on June 7th, 2023, at the LD Micro Conference in Los Angeles.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:03 am

FGEN

Fibrogen's Phase 3 Lelantos-1 trial of Pamrevlumab for non-ambulatory patients with Duchenne Muscular Dystrophy failed to meet the primary endpoint of Performance of the Upper Limb 2.0 score at week 52 compared to baseline.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 10:57 am

CHEK

HC Wainwright & Co. analyst Yi Chen has downgraded Check-Cap (NASDAQ:CHEK) from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 10:51 am